Systemic Anticoagulant Prophylaxis for Central Catheter–Associated Venous Thrombosis in Cancer Patients

Abstract

Available data do not support the routine use of anticoagulants for thromboprophylaxis to prevent CVC-related thrombosis. However, several inconsistencies can be found in the studies done to date. More studies are needed to identify subsets of cancer patients who are at higher risk of developing CVC thrombosis and may benefit from prophylactic systemic anticoagulation.

Vascular Access in Oncology Patients

“…[85][86][87] The choice to start prophylaxis against venous thromboembolic events in all oncology patients bearing a CVC, either with LMWH or with minidose warfarin, remains unsupported by evidence-based medicine. However, more studies are needed to identify subsets of cancer patients who are at high risk of developing CVC thrombosis and may benefit from prophylactic systemic anticoagulation.…”

Thromboprophylaxis for catheter‐related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials

“…Thromboprophylaxis for catheter‐related thrombosis in cancer patients remains controversial. Indeed, two systematic reviews were recently published on thromboprophylaxis in cancer patients with central venous catheters [1,2]. Our meta‐analysis expands and updates this literature by incorporating data from two further multi‐center, randomized trials.…”

Portkatheteranlage, -pflege und -komplikationen

“…Monreal u. Mitarb. konnten in einer Untersuchung den Nutzen einer Thromboseprophylaxe zeigen [23], während sich in aktuelleren randomisierten Studien sowie einer Metaanalyse kein signifikanter Effekt auf die Senkung thromboembolischer Ereignisse durch zentralvenöse Katheter nachweisen ließ [24,27].…”